Tauriga Sciences Inc. Completes Production Cycle of 18,000 Dark Chocolate Medallions, 25mg CBD Infused
1) 11_17 Image RP
TAURI dark chocolate medallion, infused with CBD (25 mg)
These dark chocolate medallions are Kosher and Halal certified and bear the name: TAURI
NEW YORK, NY, November 17, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a diversified New York-based life sciences company, today announced that it has completed its production run of 18 000 medallions of dark chocolate, infused with CBD (25 mg). These lockets will be sold in sets of 10 – for $ 39.99. This product is kosher certified (authority: Orthodox Union) and halal certified (authority: Etimad).
The arrival of these dark chocolate medallions comes just in time for Hanukkah!
The Company is gearing up for a strong holiday season 2021, building on what has already been a very good quarter (midway through).
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a diverse and income-generating life sciences company engaged in several major business activities and initiatives. The Company manufactures and distributes several proprietary retail products and product lines, primarily focused on the cannabidiol (“CBD”) and cannabigerol (“CBG”) edibles market segment. The main product line, under the Tauri-Gum ™ brand, consists of an exclusive supplement of certified kosher, halal and vegan certified chewing gum (Tauri-Gum ™ aromas infused with CBD: mint, blood orange, pomegranate), (infused with CBG Tauri-Gum ™ Flavors: Peach-Lemon, Blackcurrant), (DELTA 8 THC Infused Tauri-Gum ™ Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum ™ Flavor: Bellini Pear), (Caffeine Infused Tauri-Gum ™ Flavor: Cherry Lime Rickey) & (Tauri-Gum ™ Flavor infused with Vitamin D3: Golden Raspberry). The Company’s marketing strategy consists of a broad range of retail customers, distributors and a rapidly growing e-commerce business segment (e-commerce website: www.taurigum.com). Please visit our corporate website, for more information, as well as inquiries, at http://www.tauriga.com
Its ongoing pharmaceutical development initiative is complementary to the Company’s retail activities. This concerns the development of a proposed pharmaceutical grade version of Tauri-Gum ™, for the regulation of nausea (specifically designed for the following indication: patients undergoing chemotherapy treatment in progress). On March 22, 2021, the Company announced that it had converted its provisional U.S. patent application (filed March 17, 2020) to a non-provisional U.S. patent application. The patent, filed with the USPTO, is entitled “DRUG CBD COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF TREATMENT”. On December 18, 2020, the Company announced that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.
The company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full-time e-commerce distribution centers: one located in Montgomery, Texas, and the other in Brooklyn, New York.
DISCLAIMER – Forward-looking statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, which represent the opinions and assumptions of management regarding future events. These forward-looking statements are often indicated using words such as “may”, “will”, “expects”, “anticipates”, “believes”, “hopes”, “believes” or plans, and may include statements regarding business objectives such as as well as the achievement of certain business goals and milestones. Forward-looking statements are based on current circumstances and on management’s current beliefs regarding events that have not occurred, which may not occur, or which may occur with consequences or timing different from those currently believed or anticipated. . Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as general economic and business conditions, the ability to develop and successfully market products, consumer and business consumption habits, the ability to complete acquisition and licensing transactions, exchange rate fluctuations and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in more detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update any forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Tauriga Sciences, Inc.
4 Cour de Nancy, office 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: [email protected]
cell # (917) 796 9926
Company Instagram: @tauricum
Personal Instagram: @ sethsms47
Company website: www.tauriga.com
E-commerce site: www.taurigum.com